Hansoh Pharmaceutical Group Company Limited (SEHK: 3692)
Health Care · Pharmaceuticals · CN
HK$33.08
-0.66% today · -11.7% 1Y
Hansoh Pharmaceutical Group Company Limited (SEHK: 3692) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $25.58B and employs 9,347 people.
Over the last twelve months the share price has lost 11.7%, trading between 28.06 and 44.22.
Tweenvest scores Hansoh Pharmaceutical Group Company Limited across four factors: quality 89/100, value 34/100, growth 87/100, dividend 76/100. Its strongest factor is quality.
3692 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $25.58B
- Revenue (TTM)
- $2.15B
- P/E
- 32.00
- EPS
- 0.93
- Dividend yield
- 1.30%
- Beta (5Y)
- 0.56
- 52-week high
- HK$44.22
- 52-week low
- HK$28.06
- Avg volume (3M)
- —
- Shares outstanding
- 6.06B
- Employees
- 9,347
- Next earnings
- —
About Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
- ISIN
- KYG549581067
- Founded
- 1995
- Listed since
- Jun 14, 2019
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.